drugset / Trial / NCT02182531

Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers

NCT02182531

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the bioavailable fraction of epinastine and pseudoephedrine when administered as a fixed dose combination in tablet form (new pharmaceutical formulation), with that obtained with each of these drugs when administered separately to healthy volunteers.

Timeline

Start
1999-08
Primary completion
1999-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule
Subject Pseudoephedrine Small molecule

Indications

No indication recorded.